Viridian Therapeutics, Inc. Common Stock Earnings Dividend

Viridian Therapeutics, Inc. Common Stock’s revenue jumped 95.83% since last year same period to $0.14Mn in the Q1 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated 6.82% jump in its revenue since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s net profit fell -20.7% since last year same period to $-104.9Mn in the Q1 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated 12.84% jump in its net profits since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s net profit margin jumped 38.37% since last year same period to -74397.87% in the Q1 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated 18.4% jump in its net profit margins since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.97 - a 11.01% jump from last quarter’s estimates.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.97.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -3.45% since last year same period to -0.9 in the Q1 2026. This indicates that the Viridian Therapeutics, Inc. Common Stock has generated -3.45% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Viridian Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at -0.33.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Viridian Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at -0.58.